Daewoong Pharmaceutical, TionLab Therapeutics join hands to develop monthly obesity injectable

Daewoong Pharmaceutical said Friday it signed a strategic partnership agreement with TionLab Therapeutics to jointly develop and commercialize long-acting monthly semaglutide injectable to the global market. The agreement is characterized as an open innovation model, combining the capabilities of a bio startup and a leading pharmaceutical. With TionLab’s long-acting drug transmission platform technologies and Daewoong’s expertise in development and commercialization, both parties aim to secure a

By The Korea Herald